Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. (Q45928394)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 July 2009

Language	Label	Description	Also known as
English	Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.	scientific article published on 15 July 2009

Statements

scholarly article

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. (English)

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Domenica Lorusso

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

author name string

G Ferrandina

2

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

S Pignata

3

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

M Ludovisi

4

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

R Viganò

5

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

S Scalone

6

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

P Scollo

7

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

E Breda

8

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

A Pietragalla

9

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

G Scambia

10

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

publication date

15 July 2009

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

Annals of Oncology

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

21

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

1

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

61-66

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II study of ifosfamide and mesna in patients with previously-treated carcinoma of the cervix. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of vinorelbine in persistent or recurrent nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP266

21 January 2018

Identifiers

10.1093/ANNONC/MDP266

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

1 reference

Europe PubMed Central

17 December 2017

http://europepmc.org/abstract/MED/19605508

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45928394&oldid=1802494429"